Poster Session from ASCO 2015:

ONT-380 in the Treatment of HER2– Breast Cancer Central Nervous System Metastases (Cristiano Ferrario)

An Indirect Evaluation of Bone Saturation With Zoledronic Acid After Long-Term Q4 Week Dosing Using Plasma and Urine Pharmacokinetics. First (Gabriel N. Hortobagyi)

Safety of Trastuzumab Emtansine (T-DM1) in 373 Patients 65 Years or Older with HER2-Positive Advanced Breast Cancer: A Subgroup Analysis of the Kamilla Study (Carlos H. Barrios)

Meta-Analysis of Clinical Outcomes to Second-Line Endocrine Therapy for Visceral and Non-Visceral Metastases (John Forsyth Russell)

Hormonal Treatment and Late Recurrence in Early-Stage Breast Cancer Patients (Carlos Hernando Barcenas)

Effect of Tumor Infiltrating Lymphocytes and Stromal CD68 on Trastuzumab Benefit in Early Stage HER2-Positive Breast Cancer (Jacques Raphael)